Drug Approval | June 27, 2022
Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
The innovative software module is designed to meet growing scientific demand from researchers and drug developers
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
The rally attracted around 250 riders, including professionals and amateurs.
To address the preventive & primary healthcare delivery gaps in India
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
Peacock also serves as a Director and Chair of the Audit and Finance Committee of UCB SA, a biopharmaceutical company focusing on neurology and immunology
Subscribe To Our Newsletter & Stay Updated
